Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 14/20 | 0.45 |
| ▸ | PRF1 | P14222 | 3/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2589628 | 0.91 | PRF1 (0.45) | PDE4DPRF1CYP3A4PDE4APDE4B | |
| SCHEMBL2593953 | 0.86 | PDE4D (0.42) | PDE4DPRF1CYP3A4 | |
| SCHEMBL7708080 | 0.86 | PRF1 (0.41) | PDE4DPRF1CYP3A4PDE4APDE4B | |
| SCHEMBL2591930 | 0.85 | PRF1 (0.39) | PDE4DPRF1CYP3A4PDE4APDE4B | |
| SCHEMBL7706052 | 0.82 | PRF1 (0.39) | PDE4DPRF1CYP3A4PDE4APDE4B | |
| SCHEMBL2584164 | 0.81 | PRF1 (0.49) | PDE4DPRF1CYP3A4KDM4ELMNA | |
| SCHEMBL2591212 | 0.80 | PRF1 (0.44) | PDE4DPRF1CYP3A4PDE4APDE4B | |
| SCHEMBL2584274 | 0.80 | PRF1 (0.42) | PDE4DPRF1CYP3A4PDE4APDE4B | |
| SCHEMBL2591559 | 0.79 | PDE4D (0.41) | PDE4DPRF1CYP3A4PDE4APDE4B | |
| SCHEMBL2588578 | 0.79 | PRF1 (0.43) | PDE4DPRF1CYP3A4PDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011134468-A1 | BIARYL PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2011-11-03 | — | — | WO | disclosed |